Hepatitis Monthly

Published by: Kowsar

Hepatitis C Virus - Related Hepatocellular Carcinoma in the Era of Direct - Acting Antiviral Agents

Xu Liu 1 , Yanhang Gao 1 , ** and Junqi Niu 1 , *
Authors Information
1 Department of Hepatology, First Hospital of Jilin University, Changchun, China
Corresponding Authors:
Article information
  • Hepatitis Monthly: June 2018, 18 (6); e66007
  • Published Online: April 28, 2018
  • Article Type: Review Article
  • Received: January 8, 2018
  • Revised: March 21, 2018
  • Accepted: March 26, 2018
  • DOI: 10.5812/hepatmon.66007

To Cite: Liu X, Gao Y, Niu J. Hepatitis C Virus - Related Hepatocellular Carcinoma in the Era of Direct - Acting Antiviral Agents, Hepat Mon. 2018 ; 18(6):e66007. doi: 10.5812/hepatmon.66007.

Copyright © 2018, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
  • 1. World Health Organization. Hepatitis C Fact sheets. [cited October]. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/.
  • 2. Cortez KJ, Kottilil S. Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C. Ther Adv Chronic Dis. 2015;6(1):4-14. doi: 10.1177/2040622314551934. [PubMed: 25553238].
  • 3. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 2001;34(4 Pt 1):809-16. doi: 10.1053/jhep.2001.27831. [PubMed: 11584380].
  • 4. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557-76. doi: 10.1053/j.gastro.2007.04.061. [PubMed: 17570226].
  • 5. Zamor PJ, deLemos AS, Russo MW. Viral hepatitis and hepatocellular carcinoma: etiology and management. J Gastrointest Oncol. 2017;8(2):229-42. doi: 10.21037/jgo.2017.03.14. [PubMed: 28480063].
  • 6. Nguyen LH, Nguyen MH. Systematic review: Asian patients with chronic hepatitis C infection. Aliment Pharmacol Ther. 2013;37(10):921-36. doi: 10.1111/apt.12300. [PubMed: 23557103].
  • 7. Nguyen MH, Whittemore AS, Garcia RT, Tawfeek SA, Ning J, Lam S, et al. Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol. 2004;2(9):820-4. [PubMed: 15354283].
  • 8. El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014;60(5):1767-75. doi: 10.1002/hep.27222. [PubMed: 24839253].
  • 9. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529-38. doi: 10.1016/j.jhep.2006.05.013. [PubMed: 16879891].
  • 10. Li H. Retrospective analysis of the clinical features of 876 cases of patients with primary liver cancer. Jilin: Jilin University; 2016.
  • 11. Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, et al. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122(9):1312-37. doi: 10.1002/cncr.29936. [PubMed: 26959385].
  • 12. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10(9):553-62. doi: 10.1038/nrgastro.2013.107. [PubMed: 23817321].
  • 13. Beste LA, Leipertz SL, Green PK, Dominitz JA, Ross D, Ioannou GN. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013. Gastroenterology. 2015;149(6):1471-82. quiz e17-8. doi: 10.1053/j.gastro.2015.07.056. [PubMed: 26255044].
  • 14. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000;160(21):3227-30. [PubMed: 11088082].
  • 15. Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2015;62(1 Suppl):S87-99. doi: 10.1016/j.jhep.2015.02.006. [PubMed: 25920094].
  • 16. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9(6):509-16. doi: 10.1016/j.cgh.2011.03.004. [PubMed: 21397729].
  • 17. Van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584-93. doi: 10.1001/jama.2012.144878. [PubMed: 23268517].
  • 18. Hu P, Ren H. [Current status of treatment of chronic hepatitis C and related challenges in the "Pre-DAA Era" in China]. Zhonghua Gan Zang Bing Za Zhi. 2016;24(11):869-73. doi: 10.3760/cma.j.issn.1007-3418.2016.11.015. [PubMed: 27978936].
  • 19. Xiaoyu W, Junqi N. Mechanism of action of direct-acting antiviral agents in treatment of chronic hepatitis C. Linchuang Gandanbing Zazhi. 2016;32(9):1699-705.
  • 20. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77-87. doi: 10.1002/hep.27259. [PubMed: 25069599].
  • 21. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580-93. doi: 10.1056/NEJMoa0808010. [PubMed: 19625712].
  • 22. Singal AG, Waljee AK, Shiffman M, Bacon BR, Schoenfeld PS. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. Aliment Pharmacol Ther. 2010;32(8):969-83. doi: 10.1111/j.1365-2036.2010.04427.x. [PubMed: 20937042].
  • 23. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483-93. doi: 10.1056/NEJMoa1316366. [PubMed: 24725238].
  • 24. Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015;373(8):705-13. doi: 10.1056/NEJMoa1501315. [PubMed: 26196665].
  • 25. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604-14. doi: 10.1056/NEJMoa1401561. [PubMed: 24720679].
  • 26. Miyake Y, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat. 2010;17(4):287-92. doi: 10.1111/j.1365-2893.2009.01181.x. [PubMed: 19732321].
  • 27. Hsu YC, Ho HJ, Wu MS, Lin JT, Wu CY. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatology. 2013;58(1):150-7. doi: 10.1002/hep.26300. [PubMed: 23389758].
  • 28. Harada N, Hiramatsu N, Oze T, Tatsumi T, Hayashi N, Takehara T. Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study. J Med Virol. 2015;87(7):1199-206. doi: 10.1002/jmv.24173. [PubMed: 25772024].
  • 29. Chang CY, Nguyen P, Le A, Zhao C, Ahmed A, Daugherty T, et al. Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease. Medicine (Baltimore). 2017;96(6). e6128. doi: 10.1097/MD.0000000000006128. [PubMed: 28178174].
  • 30. Prenner SB, VanWagner LB, Flamm SL, Salem R, Lewandowski RJ, Kulik L. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol. 2017;66(6):1173-81. doi: 10.1016/j.jhep.2017.01.020. [PubMed: 28161470].
  • 31. Beste LA, Green PK, Berry K, Kogut MJ, Allison SK, Ioannou GN. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol. 2017;67(1):32-9. doi: 10.1016/j.jhep.2017.02.027. [PubMed: 28267622].
  • 32. Tammineedi D, Eisert J, Ukken J, Froehlich M, Azab M, Liu X, et al. More extended indication of DAA therapy in patients with HCC, affordability, and further statistical considerations. J Hepatol. 2017. doi: 10.1016/j.jhep.2017.08.035. [PubMed: 28958883].
  • 33. Wirth TC, Manns MP. The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma. Ann Oncol. 2016;27(8):1467-74. doi: 10.1093/annonc/mdw219. [PubMed: 27226385].
  • 34. Hengst J, Falk CS, Schlaphoff V, Deterding K, Manns MP, Cornberg M, et al. Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C. J Infect Dis. 2016;214(12):1965-74. doi: 10.1093/infdis/jiw457. [PubMed: 27683821].
  • 35. Charlton M, Gane E, Manns MP, Brown RS Jr, Curry MP, Kwo PY, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148(1):108-17. doi: 10.1053/j.gastro.2014.10.001. [PubMed: 25304641].
  • 36. Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015;61(5):1485-94. doi: 10.1002/hep.27681. [PubMed: 25557906].
  • 37. MacParland SA, Pham TN, Guy CS, Michalak TI. Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity in vitro. Hepatology. 2009;49(5):1431-41. doi: 10.1002/hep.22802. [PubMed: 19177592].
  • 38. Buonfiglioli F, Conti F, Andreone P, Crespi C, Foschi FG, Lenzi M, et al. Development of Hepatocellular Carcinoma in HCV Cirrhotic Patients Treated with Direct Acting Antivirals. J Hepatol. 2016;64(2). S215. doi: 10.1016/s0168-8278(16)00183-5.
  • 39. Ravi S, Axley P, Jones D, Kodali S, Simpson H, McGuire BM, et al. Unusually High Rates of Hepatocellular Carcinoma After Treatment With Direct-Acting Antiviral Therapy for Hepatitis C Related Cirrhosis. Gastroenterology. 2017;152(4):911-2. doi: 10.1053/j.gastro.2016.12.021. [PubMed: 28161225].
  • 40. Cardoso H, Vale AM, Rodrigues S, Goncalves R, Albuquerque A, Pereira P, et al. High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis. J Hepatol. 2016;65(5):1070-1. doi: 10.1016/j.jhep.2016.07.027. [PubMed: 27476768].
  • 41. Zeng QL, Li ZQ, Liang HX, Xu GH, Li CX, Zhang DW, et al. Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: Too alarming? J Hepatol. 2016;65(5):1068-9. doi: 10.1016/j.jhep.2016.07.029. [PubMed: 27476763].
  • 42. Kobayashi M, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, et al. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. J Med Virol. 2017;89(3):476-83. doi: 10.1002/jmv.24663. [PubMed: 27531586].
  • 43. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017;153(4):996-1005 e1. doi: 10.1053/j.gastro.2017.06.012. [PubMed: 28642197].
  • 44. Li DK, Ren Y, Fierer DS, Rutledge S, Shaikh OS, Lo Re V, et al. The short‐term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct‐acting antivirals: An ERCHIVES study. Hepatol. 2017. doi: 10.1002/hep.29707. [PubMed: 29205416].
  • 45. Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2017. doi: 10.1016/j.jhep.2017.08.030. [PubMed: 28887168].
  • 46. Cheung MCM, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;65(4):741-7. doi: 10.1016/j.jhep.2016.06.019. [PubMed: 27388925].
  • 47. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65(4):727-33. doi: 10.1016/j.jhep.2016.06.015. [PubMed: 27349488].
  • 48. Rinaldi L, Di Francia R, Coppola N, Guerrera B, Imparato M, Monari C, et al. Hepatocellular carcinoma in HCV cirrhosis after viral clearance with direct acting antiviral therapy: preliminary evidence and possible meanings. World Canc Res J. 2016;3(3). e748.
  • 49. Nagaoki Y, Imamura M, Aikata H, Daijo K, Teraoka Y, Honda F, et al. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy. PLoS One. 2017;12(8). e0182710. doi: 10.1371/journal.pone.0182710. [PubMed: 28797106].
  • 50. Strazzulla A, Iemmolo RMR, Carbone E, Postorino MC, Mazzitelli M, De Santis M, et al. The Risk of Hepatocellular Carcinoma After Directly Acting Antivirals for Hepatitis C Virus Treatment in Liver Transplanted Patients: Is It Real? Hepat Mon. 2016;16(11). e41933. doi: 10.5812/hepatmon.41933. [PubMed: 28070200].
  • 51. Reig M, Marino Z, Perello C, Inarrairaegui M, Ribeiro A, Lens S, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65(4):719-26. doi: 10.1016/j.jhep.2016.04.008. [PubMed: 27084592].
  • 52. Yang JD, Aqel BA, Pungpapong S, Gores GJ, Roberts LR, Leise MD. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. J Hepatol. 2016;65(4):859-60. doi: 10.1016/j.jhep.2016.06.023. [PubMed: 27392425].
  • 53. El Kassas M, Funk AL, Salaheldin M, Shimakawa Y, Eltabbakh M, Jean K, et al. Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: A comparative analysis. J Viral Hepat. 2017. doi: 10.1111/jvh.12854. [PubMed: 29274197].
  • 54. Villani R, Facciorusso A, Bellanti F, Tamborra R, Piscazzi A, Landriscina M, et al. DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment. PLoS One. 2016;11(12). e0167934. doi: 10.1371/journal.pone.0167934. [PubMed: 27997563].
  • 55. Llovet JM, Villanueva A. Liver cancer: Effect of HCV clearance with direct-acting antiviral agents on HCC. Nat Rev Gastroenterol Hepatol. 2016;13(10):561-2. doi: 10.1038/nrgastro.2016.140. [PubMed: 27580683].
  • 56. Lu Y, Jiang Z, Dai H, Miao R, Shu J, Gu H, et al. Hepatic leukocyte immunoglobulin-like receptor B4 (LILRB4) attenuates nonalcoholic fatty liver disease via SHP1-TRAF6 pathway. Hepatology. 2018;67(4):1303-19. doi: 10.1002/hep.29633. [PubMed: 29091299].
  • 57. Anrs collaborative study group on hepatocellular carcinoma . Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol. 2016;65(4):734-40. doi: 10.1016/j.jhep.2016.05.045. [PubMed: 27288051].
  • 58. Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavo MR, Madonia S, et al. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Aliment Pharmacol Ther. 2017;46(7):688-95. doi: 10.1111/apt.14256. [PubMed: 28791711].
  • 59. Ikeda K, Kawamura Y, Kobayashi M, Kominami Y, Fujiyama S, Sezaki H, et al. Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma. Dig Dis Sci. 2017;62(10):2932-42. doi: 10.1007/s10620-017-4739-z. [PubMed: 28884320].
  • 60. Minami T, Tateishi R, Nakagomi R, Fujiwara N, Sato M, Enooku K, et al. The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma. J Hepatol. 2016;65(6):1272-3. doi: 10.1016/j.jhep.2016.07.043. [PubMed: 27524465].
  • 61. Torres HA, Vauthey JN, Economides MP, Mahale P, Kaseb A. Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment. J Hepatol. 2016;65(4):862-4. doi: 10.1016/j.jhep.2016.05.034. [PubMed: 27255582].
  • 62. Zavaglia C, Okolicsanyi S, Cesarini L, Mazzarelli C, Pontecorvi V, Ciaccio A, et al. Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured? J Hepatol. 2017;66(1):236-7. doi: 10.1016/j.jhep.2016.08.016. [PubMed: 27592303].
  • 63. Nguyen K, Jimenez M, Moghadam N, Wu C, Farid A, Grotts J, et al. Decrease of Alpha-fetoprotein in Patients with Cirrhosis Treated with Direct-acting Antivirals. J Clin Transl Hepatol. 2017;5(1):43-9. doi: 10.14218/JCTH.2016.00057. [PubMed: 28507926].
  • 64. Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol. 2017;67(6):1204-12. doi: 10.1016/j.jhep.2017.07.025. [PubMed: 28802876].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments